Avian #Influenza #Report: July 12 - 18 '26 (Wk 29) (HK CHP, July 21 '26): 1 New #Human Case of Infection with #H5 virus in #Bangladesh

 

{Excerpt}

(...)

    ° Avian influenza A(H5): 

        § Bangladesh: 

            - Sylhet Division: A child with onset on May 17, 2026. 

(...)

Source: 

Link: https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk29.pdf

____

#Togo - High pathogenicity avian #influenza #H5N1 viruses (Inf. with) (#poultry) - Immediate notification

 

Poultry farms in the Maritime Region.

Source: 

Link: https://wahis.woah.org/#/in-review/7714

____

Loss of #hemagglutination ability by #H3N2 #influenza A virus, subclade K.

 

Abstract

Seasonal human H3N2 influenza viruses, subclade K (J.2.4.1), have been the predominant influenza A viruses in the Northern hemisphere influenza season of 2025/2026. Since 2024, the vaccine virus A/Darwin/6/21 has emerged in different antigenic variants. Antigenic changes are frequently caused by amino acid substitutions near the hemagglutinin (HA) receptor-binding pocket, which can also affect receptor binding properties, such as hemagglutination. Hemagglutination is crucial for assessing antigenicity using the hemagglutination inhibition (HAI) assay, and a loss of binding to turkey erythrocytes could significantly hamper this process. In this study, we explored how substitutions in or around the HA receptor-binding site affect binding to glycans at the molecular level. We employed ELISA, glycan array, flow cytometry, hemagglutination assays, and tissue staining. Substitutions at positions 140, 192, and 223 establish clade J viruses that emerged in 2024. Computational analysis of HA in complex with an elongated glycan reveals that mutation F192 forms a CH-Pi interaction to stabilize the binding. Based on this background, substitutions in antigenic sites A and B within subclade K viruses exhibit a binding preference for elongated glycans, which are not displayed on turkey erythrocytes. Conversely, our previously established glyco-remodeled erythrocytes are efficiently bound by these subclade K H3N2 viruses and could support influenza surveillance and vaccine development.

Competing Interest Statement

The authors have declared no competing interest.

Funder Information Declared

CSC fellowship, (202209120001)

National Institute of Allergy and Infectious Diseases, R01 AI165692

Source: 

Link: https://www.biorxiv.org/content/10.64898/2026.07.20.739523v1

____

Highly Pathogenic Avian #Influenza #H5N5 in a Polar #Bear and Atlantic #Walrus, #Svalbard, 2026, with Widespread Seroconversion in Polar Bears

 

Abstract

Highly pathogenic avian influenza virus (HPAIV) subtype H5N5 was detected in a one-year-old polar bear (Ursus maritimus) and an adjacent adult Atlantic walrus (Odobenus rosmarus rosmarus), both found deceased in Raudfjorden, Svalbard. This represents the first confirmed case of HPAI in a European polar bear and the second in an Atlantic walrus. Viral genomes were nearly identical and harbored PB2-E627V, a marker associated with mammalian adaptation. Several polar bears, including the deceased individual, had previously been observed feeding on the walrus carcass. Antibodies against H5 were detected in 75% of polar bears in 2023 (n=36) and 97% in 2024-2025 (n=65), suggesting extensive circulation of HPAIV in the population following the first detections in birds in Svalbard in 2022, whereas no antibodies were detected in samples from 2014-2022 (n=243).

Competing Interest Statement

The authors have declared no competing interest.

Funder Information Declared

Project OH4Surveillance, funded by the European Union, Grant Agreement No 101132473

Morris Animal Foundation, Grant ID# D25ZO-430; KJB

Norwegian Veterinary Institute, 12311 SvalVilt

Source: 

Link: https://www.biorxiv.org/content/10.64898/2026.07.20.739480v1

____

#Taiwan, Domestic #COVID19 activity continues to rise, population is urged to get vaccinated (CDC, July 21 '26): NB.1.8.1 variant dominant

 

{Excerpt}

(...)

    According to data from the Taiwan Centers for Disease Control and Prevention (CDC), the COVID-19 epidemic in Taiwan continues to rise and has reached the epidemic threshold, entering its epidemic period. 

    In week 28 (July 12-18), there were 4,766 outpatient and emergency room visits, a 66.5% increase compared to the previous 7 days (July 5-11). 

    Last week (July 14-20), there were 25 new locally transmitted severe cases and 5 new locally transmitted deaths. 

    Since October 2025, a total of 161 local cases of COVID-19 complicated with severe illness have been reported, including 23 deaths. 

    The majority of severe cases were among those aged 65 and above (74.5%) and those with a history of chronic diseases (83.9%). 

    92.5% of these cases were not vaccinated against COVID-19 this season. 

    Clinical manifestations were mainly upper respiratory symptoms, including sore throat, cough, nasal congestion, runny nose, fever, fatigue, headache, and muscle aches. 

    A very small number of cases experienced temporary loss or dullness of smell or taste. 

    In the past four weeks, the dominant local variant strain has been NB.1.8.1. 

    The global positivity rate has recently increased slightly, with the exception of the Western Pacific Region, which is showing an upward trend, while other regions have shown a downward or stable trend. 

    The epidemic is rising in neighboring countries/regions such as China, Hong Kong, Japan, and South Korea. 

    Currently, the dominant global variant strain is NB.1.8.1 (58.76%), followed by XFG (19.07%) and JN.1 (15.46%).

(...)

Source: 

Link: https://www.cdc.gov.tw/Bulletin/Detail/u3YrvIQXQrOtbJXDXxFxQg?typeid=9

____

Detection of #H5N1 HPAIV Clade 2.3.4.4b Avian #Influenza Virus in Backyard #Chickens in #CostaRica

 

Abstract

Influenza A virus is a segmented, negative-sense RNA virus. Since the early 2020s, H5 clade 2.3.4.4b viruses have spread widely across Europe, Africa, and Asia, affecting wild birds and poultry. Costa Rica reported its first H5 clade 2.3.4.4b avian influenza virus (AIV) case on 19 January 2023. This study describes an outbreak in backyard chickens and ducks. Initial serum samples collected on 24 January showed three chickens negative for AIV, while one duck tested positive by ELISA and agar gel immunodiffusion (AGID). During a second visit on 27 January, three of four chicken sera collected tested positive by ELISA and AGID. Tissue samples were positive for influenza A by qRT-PCR. Next-generation sequencing recovered five of the eight viral genomic segments, and the hemagglutinin cleavage site sequence (REKRRKR↓G) confirmed a highly pathogenic avian influenza virus (HPAIV) H5 strain. The samples were submitted to the National Veterinary Services Laboratories for confirmation. Serological testing showed reactivity to North American low pathogenic H5 antigens, and qRT-PCR amplified influenza A and N1 genes. Virus isolation and next-generation sequencing (NGS) of all eight viral genome segments were successfully performed at the WHO Collaborating Centre at St. Jude Children’s Research Hospital (SJCRH).

Source: 

Link: https://www.mdpi.com/1999-4915/18/7/799

____

Multiorgan #Outcomes Following #BNT162b2 #mRNA #Vaccination vs #SARS-CoV-2 #Infection: A 30-Million-Person Real-World Cohort Analysis

 

Abstract

SARS-CoV-2 infection and BNT162b2 mRNA vaccination carry distinct cardiovascular risk profiles, yet direct comparative evidence across all immunological exposure groups and both sexes remains limited. Using the TriNetX Research Network (December 2020–December 2024), we stratified 30.3 million individuals into four mutually exclusive cohorts: uninfected/unvaccinated controls (G1), infected/unvaccinated (G2), vaccinated-only (G3), and hybrid immunity (G4). Fifty prespecified cardiovascular, cerebrovascular, and mortality outcomes were evaluated across four temporal windows (0–3, 3–6, 6–9, and >9 months) with analyses stratified by biological sex. SARS-CoV-2 infection was associated with 3- to 5-fold increases in cardiovascular events during the acute phase, including myocarditis (males: RR 4.44; females: RR 5.59) and all-cause mortality (males: RR 4.53), with risks persisting beyond nine months. BNT162b2 vaccination conferred 65-76% reductions in major adverse cardiovascular events (0–3 months). Post-infection vaccination (hybrid immunity) provided an additional 36–38% MACE reduction; males exhibited late pericarditis elevation beyond nine months. Completing the two-dose primary series maximally reduced mortality (by 77%) and myocarditis (by 62%) versus single dosing. In this US cohort, SARS-CoV-2 infection confers substantially greater and more sustained cardiovascular risk than BNT162b2 vaccination across all comparisons and both sexes, consistent with a favorable cardiovascular risk-benefit profile for vaccination.

Source: 

Link: https://www.nature.com/articles/s41541-026-01528-3

____

Excess #mortality attributable to the 2025 #Iberian Peninsula #blackout

 

Abstract

On 28 April 2025, a widespread power outage affected mainland Portugal and Spain for around ten hours, causing major disruptions and eight reported deaths. Health impacts of blackouts range from direct effects, such as medical equipment failure, to indirect effects such as disrupted healthcare. Here we show that the 2025 Iberian blackout is associated with increased mortality in Spain, but not in Portugal. We find little evidence of excess mortality on the day of the event itself. In Spain, however, mortality rises over the next two days (+167 deaths; 95% credible interval: +28 to +300; +2.4% relative increase), particularly among women aged 85+. We also observe regional differences, but their drivers remain uncertain and may include variation in outage severity, underlying vulnerabilities, or local health-system and infrastructure conditions. These findings highlight the underestimated health burden of blackouts and the need for improved preparedness in a changing climate.

Source: 

Link: https://www.nature.com/articles/s41467-026-75581-w

____

#Genomic Characterization of #SARS-CoV-2 #NB.1.8.1 and #PQ.2 from the #Infants and Young #Children with #Gastrointestinal Symptoms

 

Abstract

Purpose: 

This study investigated the viral genomic characteristics of infants and young children who presented to our hospital with gastrointestinal symptoms during a local COVID-19 epidemic and were confirmed to have SARS-CoV-2 infection.

Patients and methods: 

Between May and August 2025, pharyngeal swab samples were collected from four infants and young children who presented to the outpatient department of Meizhou People’s Hospital in Meizhou, with gastrointestinal symptoms. Nucleic acid testing and whole-genome sequencing were performed. The viral mutation profile was analyzed, and the potential impact of mutations on protein function was predicted.

Results: 

Pangolin typing identified the NB.1.8.1 variant in three patients and the PQ.2 variant in one patient. Genome sequences from three of the four viral variants displayed varying degrees of mutation. The nonsynonymous mutations for both variants were concentrated in the spike protein. A comparison with the parental XDV.1.5.1 lineage revealed 14 specific mutations, with 7 nonsynonymous sites conserved across all gene sequences. Five of these mutation sites, NSP12: D284Y, ORF3a: L46F, ORF3a: F207C, N: Q9H, and N: Q384H, were predicted to be functionally deleterious and structurally destabilizing.

Conclusion: 

SARS-CoV-2 variants from specimens obtained from four infants and young children exhibited varying degrees of mutation, providing evidence for the ongoing evolution of emerging variants in pediatric patients. However, monitoring genomic changes of circulating variants requires further clinical specimens, which contributes to understanding the dynamic changes at mutation sites, thereby supporting epidemic prevention and control.

Source: 

Link: https://www.dovepress.com/genomic-characterization-of-sars-cov-2-nb181-and-pq2-from-the-infants--peer-reviewed-fulltext-article-IDR

____

#Bovine-derived #H5N1 #influenza virus efficiently infects lactating #swine via the #mammary gland

 

Abstract

Since 2024, highly pathogenic influenza A(H5N1) viruses have spread extensively among U.S. dairy cattle, where they replicate efficiently in the mammary gland and are shed at high titers in milk. To directly assess susceptibility of commercial swine populations to bovine-derived H5N1 virus, lactating sows with prior influenza virus vaccination histories representative of U.S. commercial swine production systems were inoculated via the intramammary route and co-housed with their 1-week-old piglets to evaluate disease outcomes, viral replication, and potential for vertical transmission. Intramammary inoculation of lactating sows resulted in sustained viral RNA shedding in milk, while piglets exhibited sporadic oral viral RNA positivity that mirrored viral kinetics in milk. Lesions in mammary tissue and viral antigen staining, as well as development of neutralizing antibody responses and changes in milk color and consistency, further confirmed infection in the sows. Despite these molecular findings, none of the animals developed overt clinical disease, and respiratory involvement was not noted during the study period. Collectively, we demonstrate that intramammary exposure results in productive influenza A(H5N1) virus infection in lactating sows despite their vaccination histories, indicating the potential threat of viral spillover into commercial swine populations. The clinically inapparent nature of infection presents a risk of subclinical spread and underscores the importance of expanding viral surveillance to swine.

Competing Interest Statement

The authors have declared no competing interest.

Funder Information Declared

Swine Health Information Center, 25-020

United States Department of Agriculture (USDA) National Institute of Food and Agriculture (NIFA), 2025-39601-44639

National Institutes of Health, P30 CA016058

Source: 

Link: https://www.biorxiv.org/content/10.64898/2026.07.18.739312v1

____

#Canada, New Temporary #Border #Measures in Response to the #Ebola Disease #Outbreak (PHAC, July 19 '26)

 

Statement | July 19, 2026 | Ottawa, Ontario | Public Health Agency of Canada

    In response to the ongoing Ebola disease outbreak in the Democratic Republic of the Congo, the Government of Canada is taking decisive action and implementing new temporary border measures to reduce the risk of the disease entering and spreading within Canada. 

    As of Monday, July 20, 2026, 11:59 p.m. EDT, any foreign national who was in the Democratic Republic of the Congo within the past 21 days will be prohibited from entering Canada. 

    To support this measure, an Interim Order under the Aeronautics Act is also in place, requiring commercial and private air carriers to not permit foreign nationals to board a flight to Canada.

    The Public Health Agency of Canada (PHAC) previously introduced temporary border measures under the Quarantine Act to reduce the risk of introduction and spread of Ebola disease in Canada. 

    These measures came into effect on May 30 at 11:59 p.m. EDT and are in effect until August 29, 2026. 

    These temporary border measures are out of an abundance of caution, as the health risk to Canadians from Ebola disease is considered low, and no travel-related cases have been reported in Canada to date.

    Limiting entry of foreign nationals who have been in the the DRC in the previous 21 days may reduce public health risks for Canadians and is intended to increase the effectiveness and sustainability of border measures that can safely process travelers arriving in Canada, including our returning humanitarian workers.

    There is no change for Canadian citizens, permanent residents, and persons registered under the Indian Act entering Canada who have been in the Democratic Republic of Congo, Uganda or South Sudan within the previous 21 days. 

    They will continue to be able to travel to Canada, will receive a health assessment upon arrival and be required to quarantine on arrival for 21 days. 

    This and all other measures from the previous Order in Council remain in place until August 29, 2026.

    Anyone planning to travel internationally should review the Travel Advice and Advisories page for their destination(s) before travelling. PHAC updated a level 2 travel health notice for Ebola disease in the Democratic Republic of Congo on May 19. Any travellers to Uganda should refer to the Outbreak Monitoring alert on the Travel Advice and Advisory page for that destination.

Source: 

Link: https://www.canada.ca/en/public-health/news/2026/07/new-temporary-border-measures-in-response-to-the-ebola-disease-outbreak.html

____

Standard Bearer, Aztec Art (c.1450 - c.1521)

 

{Click on Image to Enlarge}

__

Public Domain.

Source: 

Link: https://www.wikiart.org/en/aztec-art/standard-bearer-1521

____

#Coronavirus Disease Research #References (AMEDEO, July 19 '26)

 

Clin Infect Dis

1. PAYNE DC, Weinberg GA, Halasa NB, Englund JA, et al
   The New Vaccine Surveillance Network: 25 years of active, population-based surveillance for pediatric infectious diseases in the United States.
   Clin Infect Dis. 2026 Jul 13:ciag434. doi: 10.1093.
   PubMed         Abstract available
   
   
2. MEYEROWITZ EA, Richterman A
   Hantavirus on a Cruise Ship: What COVID-19 Taught Us.
   Clin Infect Dis. 2026 Jul 11:ciag428. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Emerg Infect Dis

3. FALENDER R, Kaya D, Harry M, Hachimi O, et al
   Targeted Wastewater Surveillance during the World Athletics Championship, Oregon, USA, 2022.
   Emerg Infect Dis. 2026;32.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

4. AUBRY A, Brochot E, Demey B, Louchet-Ducoroy M, et al
   Epidemiological trends in viral CNS infections in a French university hospital from 2019 to 2024, as revealed by multiplex PCR testing of cerebrospinal fluid samples.
   Int J Infect Dis. 2026 Jul 12:108977. doi: 10.1016/j.ijid.2026.108977.
   PubMed         Abstract available
   
   

   
   J Infect

5. HANSEN CL, Shaikh N, Naeger S, Torcel-Pagnon L, et al
   Hospitalizations and deaths from major respiratory viruses in the US: An ensemble time series modeling study, 2016-2025.
   J Infect. 2026;93:106811.
   PubMed         Abstract available
   
   

   
   J Med Virol

6. RIZZUTO J, Amarin JZ, Polic A, Howe HL, et al
   Severe COVID-19 in Pregnant Versus Nonpregnant Women: Intensive Care Unit Outcomes and Perinatal Risks.
   J Med Virol. 2026;98:e71036.
   PubMed         Abstract available
   
   

   
   J Virol

7. LOU J, Guo Z, Chen K, Tian Y, et al
   Cyclo-C stabilizes PEX13 to inhibit porcine epidemic diarrhea virus replication by blocking pexophagy-mediated disruption of antiviral innate immunity.
   J Virol. 2026 Jul 17:e0078526. doi: 10.1128/jvi.00785.
   PubMed         Abstract available
   
   
8. OVERSTI S, Lytras S, Kawakubo S, Ito J, et al
   From sites to structure to serology: a roadmap for structure-aware molecular evolution of antigenically evolving viruses.
   J Virol. 2026 Jul 16:e0168725. doi: 10.1128/jvi.01687.
   PubMed         Abstract available
   
   
9. KAWAHARA S, Nao N, Tulakarnwong S, Suzuki S, et al
   GC content mismatch of transgene destabilizes RNA virus genomes.
   J Virol. 2026 Jul 13:e0088226. doi: 10.1128/jvi.00882.
   PubMed         Abstract available
   
   

   
   Lancet

10. CRIVELLI L, Suemoto CK, Sosa AL, Lopera F, et al
    Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.
    Lancet. 2026 Jul 13:S0140-6736(26)01278-X. doi: 10.1016/S0140-6736(26)01278.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

11. OPPEGAARD O, Blomberg B, Cox RJ, Iversen A, et al
    Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial.
    Lancet Infect Dis. 2026 Jul 16:S1473-3099(26)00244.
    PubMed         Abstract available
    
    
12. NAIDOO T, Morgenstern C, Doohan P, Earl R, et al
    A systematic review of Nipah virus disease epidemiological parameters, outbreaks, and mathematical models.
    Lancet Infect Dis. 2026 Jul 14:S1473-3099(26)00239.
    PubMed         Abstract available
    
    

    
    N Engl J Med

13. WARKENTIN TE, Greinacher A
    Platelet-Activating Anti-Platelet Factor 4 Disorders.
    N Engl J Med. 2026 Jul 13. doi: 10.1056/NEJMra2502459.
    PubMed         Abstract available
    
    

    
    Nature

14. 
    Party pooper: grandparents' COVID risk rose after grandchildren's birthdays.
    Nature. 2026 Jul 13. doi: 10.1038/d41586-026-02194.
    PubMed        
    
    
15. GULLAND A
    This microbiologist endured a four-year court battle over COVID-19 tests.
    Nature. 2026 Jul 13. doi: 10.1038/d41586-026-01654.
    PubMed        
    

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, July 19 '26)

 

BMC Pediatr

1. CHOO MY, Lum LCS, Jalal MIA, Ooi KS, et al
   Nutritional disparities between urban poor and non-poor Malaysian children under five in the context of the COVID-19 pandemic: a cross-sectional study.
   BMC Pediatr. 2026 Jun 5. doi: 10.1186/s12887-026-07079.
   PubMed         Abstract available
   
   
2. KENDRIC KJ, Durrani TS
   Trends in pediatric household cleaning product exposures before and during the COVID-19 pandemic: a national poison data system analysis (2016-2023).
   BMC Pediatr. 2026;26:658.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

3. AMEMIYA Y, Nishiura H
   Using forensic autopsy data to estimate the age-specific infection fatality risk of COVID-19.
   Epidemiol Infect. 2026;154:e96.
   PubMed         Abstract available
   
   
4. MCGEOCH L, Stoker K, Rome M, Carey C, et al
   What is the burden of respiratory syncytial virus outbreaks in care homes? An enhanced surveillance study in England, winter 2024/25.
   Epidemiol Infect. 2026;154:e99.
   PubMed         Abstract available
   
   

   
   J Epidemiol Community Health

5. WING K, Morton C, Mahalingasivam V, Costello RE, et al
   Occurrence and persistence of symptoms, diagnoses and prescriptions after community-diagnosed COVID-19: a matched cohort study using the OpenSAFELY platform.
   J Epidemiol Community Health. 2026;80:624-634.
   PubMed         Abstract available
   
   

   
   J Infect Dis

6. FLANNERY B, Chung JR, Holiday C, Jefferson S, et al
   Influenza Antibody Levels Associated with Laboratory-Confirmed Influenza in a Test-Negative Study Design, US Flu VE Network, November 2018-May 2019.
   J Infect Dis. 2026 Jul 17:jiag371. doi: 10.1093.
   PubMed         Abstract available
   
   
7. KAWAI N, Bando T, Kawashima T, Matsuura S, et al
   Influenza Attack Rates and Vaccine Effectiveness by Prior-Season Infection and Vaccination: A 17-Season Analysis.
   J Infect Dis. 2026 Jul 11:jiag352. doi: 10.1093.
   PubMed         Abstract available
   
   
8. ROGERS S, Sumner KM, Yang Y, Johnson E, et al
   Protective effects of influenza B neuraminidase antibodies against symptomatic influenza virus infection.
   J Infect Dis. 2026 Jul 10:jiag351. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

9. CIMINSKI K, Reuther P, Rijkers R, de Vries RP, et al
   The receptor landscape of influenza A viruses.
   J Virol. 2026 Jul 16:e0144325. doi: 10.1128/jvi.01443.
   PubMed         Abstract available
   
   
10. SHIRAZI R, Kim SY, Cruz A, Stumpff JP, et al
    RELMalpha establishes a permissive environment for influenza virus infection through direct effects on lung epithelial cells.
    J Virol. 2026 Jul 16:e0222525. doi: 10.1128/jvi.02225.
    PubMed         Abstract available
    
    

    
    Lancet

11. BLAKNEY AK, Top KA, Cowling BJ, Larson HJ, et al
    Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.
    Lancet. 2026 Jun 30:S0140-6736(26)00512-X. doi: 10.1016/S0140-6736(26)00512.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

12. DA SILVA K, Naffakh N, Rameix-Welti MA, Lemoine F, et al
    Accounting for Defective Viral Genomes in viral consensus genome reconstruction, application to influenza virus.
    PLoS Comput Biol. 2026;22:e1014115.
    PubMed         Abstract available
    
    

    
    PLoS One

13. OKUI T
    Difference in excess mortality during the COVID-19 pandemic depending on marital status in Japan.
    PLoS One. 2026;21:e0354263.
    PubMed         Abstract available
    
    
14. KARIM A, Al Mamun MA, Sultana S, Kabilan MK, et al
    Teaching persuasive essay writing online to first-year undergraduates: A phenomenological study of instructional design and learning experiences.
    PLoS One. 2026;21:e0353171.
    PubMed         Abstract available
    
    
15. MICHEL S, Kempf C, Pirschtat N, Herbstreit F, et al
    Herpesvirus reactivation is associated with mortality in critically ill ICU patients with COVID-19: Insights from a retrospective single-center analysis of 455 cases.
    PLoS One. 2026;21:e0354153.
    PubMed         Abstract available
    
    
16. MA C, Sun J, Liu Z, Zhang C, et al
    Skin manifestations of primary COVID-19 infection with the omicron variant.
    PLoS One. 2026;21:e0352201.
    PubMed         Abstract available
    
    
17. MADDEN D
    Covid-19 related excess mortality: An analysis by age for selected countries.
    PLoS One. 2026;21:e0353766.
    PubMed         Abstract available
    
    
18. BOMANS S, Michotte N, El M'Rabet I, Jimenez Garcia B, et al
    Agreement and reliability between the two-day 6-minute incremental step test and two-day cardiopulmonary exercise test in post COVID-19 condition for assessing post-exertional malaise: The REVEAL-study.
    PLoS One. 2026;21:e0353132.
    PubMed         Abstract available
    
    
19. CAPODICI A, Filippeschi A, Noci F, Michelucci A, et al
    Mapping global inequities in telemedicine implementation: An umbrella review of barriers and facilitators.
    PLoS One. 2026;21:e0351885.
    PubMed         Abstract available
    
    
20. WIELAND V, Wassmuth N, Contento L, Kuhn M, et al
    Assessment of simulation-based inference methods for stochastic compartmental models in epidemiological research.
    PLoS One. 2026;21:e0353306.
    PubMed         Abstract available
    
    
21. DILILLO KM, Forconi CS, Matta A, Melo J, et al
    Estimating SARS-CoV-2 exposure in asymptomatic hospitalized children with cancer in Western Kenya: A retrospective analysis of serological data.
    PLoS One. 2026;21:e0353284.
    PubMed         Abstract available
    
    
22. ROBINSON B, Bisaillon P, Sandhu R, Khalil M, et al
    Semi-analytical hierarchical Bayesian inference of nonlinear model structure in stochastic dynamics: Applied to compartmental models of infectious diseases.
    PLoS One. 2026;21:e0350747.
    PubMed         Abstract available
    
    
23. ROSYCHUK RJ, Lee BE, Qiu JY, Gao T, et al
    Exploring the predictability of distributed lag nonlinear models using SARS-CoV-2 wastewater-based surveillance in multiple communities in Alberta, Canada.
    PLoS One. 2026;21:e0349030.
    PubMed         Abstract available
    
    
24. KAYUMBA K, Duga A, Papa Fallah M, Tshidibi C, et al
    Adverse events following immunization during COVID-19 mass vaccination campaigns in the Democratic Republic of Congo: Findings from active safety surveillance.
    PLoS One. 2026;21:e0309628.
    PubMed         Abstract available
    
    

    
    Vaccine

25. TU T, Tseng CY, Islam MD, Hsu WL, et al
    Adjuvant-free pH-controlled aggregates of E. coli-expressed H1N1-RBD enhance neutralizing antibody responses and confer protection against influenza virus.
    Vaccine. 2026;88:128898.
    PubMed         Abstract available
    
    
26. GROOTENDORST A, Paludan-Muller AS, Madsen K, Stovring H, et al
    Expanding enhanced influenza vaccines programs for adults aged >/=65 in the Nordic region predicted to improve public health and health system resilience.
    Vaccine. 2026;88:128934.
    PubMed         Abstract available
    

History of Mass Transportation: The Czech Vagónka Studénka Class 451 Electric Multiple-Unit ''Pantograf''

 {Click on Image to Enlarge}

__

By Dezidor - Self-photographed, CC BY 3.0, https://commons.wikimedia.org/w/index.php?curid=9778201

Source: 

Link: https://en.wikipedia.org/wiki/List_of_Czech_locomotive_classes#/media/File:Jednotka_451_v_Praze_(10).jpg

____

Characterization of #bovine-derived #H5N1 viruses expressing fluorescent and luminescent reporter #proteins

ABSTRACT

Highly pathogenic avian influenza H5N1 clade 2.3.4.4b viruses present a broad host range, with recent spillover and sustained transmission in dairy cattle reported in the USA. Replication-competent reporter viruses are critical tools that enable real-time monitoring of virus replication, facilitating high-throughput screens. In this study, we engineered three recombinant H5N1 clade 2.3.4.4b reporter viruses expressing nanoluciferase (NLuc) and two fluorescent reporter proteins, miniGFP2 and UnaG within the open reading frame of the nonstructural gene of the bovine A/Cattle/Texas/063224-24-1/2024 (TX2/24) virus. All reporter viruses replicated efficiently in vitro, presenting replication kinetics comparable to the parental rTX2/24 virus, but exhibited smaller plaque sizes, suggesting reduced cell-to-cell spread. In vivo infection studies in mice showed comparable pathogenicity among all four viruses, although rTX2/24-miniGFP2 and rTX2/24-UnaG exhibited decreased virus shedding relative to rTX2/24 and rTX2/24-NLuc. Virus titrations and in situ localization of virus replication sites demonstrated robust replication in respiratory tissues, with slightly attenuated systemic dissemination of all three reporter viruses. Fluorescent virus neutralization assays using miniGFP2 and UnaG reporter viruses accurately quantified neutralizing antibody titres in sera from naturally infected dairy cattle, consistent with wild-type virus assays. Additionally, the utility of the NLuc reporter virus for antiviral screening was validated against oseltamivir in vitro. Collectively, these results establish the H5N1 TX2/24-based reporter viruses as versatile and biologically relevant tools for investigating H5N1 pathogenesis and for use in serological and antiviral drug screens.

Source: 

Link: https://www.microbiologyresearch.org/content/journal/jgv/10.1099/jgv.0.002298

____

Immune correlates of #risk for #SARS-CoV-2 #infection in #children: a prospective, community-based cohort study

 

Abstract

Few studies have characterized immune correlates of SARS-CoV-2 infection risk in children, particularly those with hybrid immunity from vaccination and prior infection. We conduct a prospective community-based cohort study of 1509 U.S. children (2022–2024), performing weekly SARS-CoV-2 PCR testing and measuring baseline binding and neutralizing antibody titers against multiple variants. Higher antibody levels, notably nucleocapsid-binding and Omicron-specific neutralizing antibodies, are significantly associated with reduced risk of SARS-CoV-2 infection after adjusting for age, recent infection, exposure settings, and temporal trends (adjusted hazard ratios ranging from 0.60 to 0.87 per positive unit difference in log10-fold antibody level (AU/mL)). Secondary analyses suggest these findings are robust to multiple stratifications of SARS-CoV-2 immune status, are relevant across different pediatric age groups, and appear to apply to both overall and symptomatic infection risk. Together, the results suggest that specific antibodies can predict relative infection risk in pediatric populations with diverse immune histories. Understanding these immune correlates may inform tailored vaccination strategies and risk assessments as SARS-CoV-2 continues to evolve.

Source: 

Link: https://www.nature.com/articles/s41467-026-74684-8

____

Case - #Fatality #Risk of #Norovirus, #England, 2022–2025

 

Abstract

Norovirus incidence increased in England during 2022–2025, when GII.17 replaced GII.4 as the dominant genotype. By using nationally linked norovirus testing and fatality data, we found age and care setting, but not genotype, were associated with case-fatality risk. Increased incidence might reflect changes in transmissibility or population immunity.

Source: 

Link: https://wwwnc.cdc.gov/eid/article/32/8/26-0091_article

____

#Ebola disease caused by #Bundibugyo virus, #DRC & #Uganda (WHO D.O.N., July 17 '26): 2124 cases & 828 deaths in DRC

 

Situation at a glance

    ° The Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo remains active, with sustained transmission driving increases in reported cases and deaths. 

    ° As of 15 July 2026, a cumulative total of 2124 confirmed cases, including 828 deaths, have been reported from the Democratic Republic of the Congo. 

    ° On 13 July 2026, German authorities informed WHO of a laboratory-confirmed case of Ebola disease caused by Bundibugyo virus in a humanitarian worker from the United States of America who was medically evacuated from the Democratic Republic of the Congo. 

    ° This is the second United States citizen to be treated in Germany, reflecting the ongoing international response efforts. 

    ° In Uganda no new cases have been reported since 21 June 2026. The most recent case was discharged from the treatment centre on 16 July after two negative tests results. 

    ° The country has therefore begun the 42-day period of enhanced surveillance required before the end of the outbreak can be declared. 

    ° National authorities in Uganda and the Democratic Republic of the Congo, in collaboration with WHO and partners, continue to implement extensive response measures. 

    ° A regional preparedness and prioritization framework continues to guide readiness activities across the African Region.

Description of the situation

    ° Since the previous  Disease Outbreak News was published on 3 July 2026, the number of confirmed cases and deaths has increased substantially in the Democratic Republic of the Congo. 

    ° In total, 2145 confirmed cases have been reported:  2124 in the Democratic Republic of the Congo (including two cases with diagnosis in the Democratic Republic of the Congo and subsequent treatment in Germany), 20 in Uganda and one in France. 

    ° A total of 830 deaths has been reported, including two in Uganda.  

    ° To date, at least 410 patients have recovered, including 390 in the Democratic Republic of the Congo, 18 in Uganda, one in France, and one in Germany.  

(...)

Democratic Republic of the Congo

    ° Since 3 July 2026, an additional 664 confirmed cases, including 376 confirmed deaths, have been reported in the Democratic Republic of the Congo. 

    ° The increase is in part due to the scale-up of surveillance activities, testing, and diagnostic capacities. 

    ° As of 15 July 2026, a total of 2124 confirmed cases, including 828 deaths (crude case fatality ratio [CFR] 39%) have been reported in the Democratic Republic of Congo. 

    ° So far, 390 patients have recovered. 

    ° Cases have been reported from 46 health zones (HZ) across five provinces:  Ituri (27/36 HZ), North Kivu (11/34 HZ), South Kivu (1/34 HZ), Haut-Uele (4/13 HZ) and Tshopo (3/23 HZ).

    ° Of the 46 affected health zones, the outbreak remains active in 38 health zones, which have reported cases within the past 21 days. The remaining health zones have not reported any new cases during this period. In the past 21 days, 969 confirmed cases, including 524 confirmed deaths, have been reported.  

    ° Ituri  remains the most affected province, accounting for 89.6% (1904/2124) of all confirmed cases and 83.6% (692/828) of all reported deaths nationwide. Within the province, the highest number of confirmed cases have been reported from Bunia (570 cases), Rwampara (418 cases), Mongbwalu (347 cases), Nizi (148 cases), and Nyankunde (99 cases) health zones.  

    ° As of 15 July, 12 693 contacts have been identified and are under follow-up across Ituri (10 183), North Kivu (2360) and Tshopo (150). Of these, 10 195 contacts have been followed up, corresponding to follow-up rates of 78.1% in Ituri, 50.0% in Tshopo and 91.7% in North Kivu. Previously listed contacts in South Kivu have completed their 21-day followup. In addition, 107 contacts of the case reported in France have been listed and are under follow-up in Kinshasa.  

    ° Infections among health workers continued to increase, with 119 confirmed cases, 61 recoveries and 36 deaths reported among health workers, corresponding to a CFR of 30.3%. This highlights persistent occupational exposure risks, inadequate infection prevention and control (IPC) implementation in health facilities, and exposure risk in the community. 

    ° The outbreak continues in a complex humanitarian and conflict-affected environment, characterized by highly mobile and often displaced populations, many of whom have limited access to basic services, including food, clean water, shelter, health care and protection.  These conditions increase the risk of transmission, particularly in overcrowded sites for internally displaced people. 

    ° Security incidents affecting health facilities, have created additional operational challenges in affected provinces, including restricted access for response teams, disruption of surveillance and response activities and an increased risk of undetected transmission. These conditions underscore the need for response efforts to be led by local leaders and anchored in communities.  

___

Figure 2: Number of confirmed cases (n = 2124), in the Democratic Republic of the Congo, by date of reporting and as of 15 July 2026 

{Click on Image to Enlarge}

__

Figure 3: Number of deaths among confirmed cases (n = 828), in the Democratic Republic of the Congo, by date of reporting and as of 15 July 2026.  

{Click on Image to Enlarge}

___

NB: Newly reported confirmed cases/deaths may be part of the backlog of samples and therefore not necessarily newly acquired infections.  

Uganda

    ° The last confirmed case was reported to be identified on 21 June 2026.  As of 14 July 2026, a cumulative total of 20 confirmed cases have been reported, including two deaths in imported cases (reported on 15 May and 5 June) and one probable case resulting in death. 

    ° Of the confirmed cases, 15 were imported cases and five were secondary cases among contacts and health workers linked to imported cases from the Democratic Republic of the Congo.  All cases were reported in Kampala District. To date, no community transmission has been in Uganda. Exposure risks have been associated with health-care settings and cross-border movements.  

    ° Following case reclassification, the number of affected healthcare workers was revised from five to four. In total, 18 recoveries have been reported. 

    ° Of the 831 contacts listed as of 28 June, 821 contacts have completed their 21-day follow-up period as of 14 July.  

    ° The most recent case was discharged from the treatment centre on 16 July after two negative tests results. This marks the start of the 42-day countdown period (twice the maximum incubation period) to ensure surveillance activities continue to be implemented and detect any cases that were missed before the declaration of the end of the outbreak. Given the ongoing outbreak in the Democratic Republic of the Congo, the risk of importation still exists.   

___

Figure 4: Number of confirmed cases (n = 20), in Uganda by date of reporting and as of 17 July 2026 

{Click on Image to Enlarge}

___

France

    ° No additional BVD cases have been reported in France since the previous update. 

    ° The imported confirmed BVD case reported on 24 June recovered and was discharged from the healthcare facility on 4 July after two negative PCR test results. No secondary transmission has been identified among the five low-risk flight contacts  placed under precautionary quarantine. These contacts  completed their follow-up period on 14 July. 

    ° French authorities have been monitoring  these individuals in coordination with relevant regional public health authorities as well as with the National IHR Focal Points of Belgium and the Netherlands who conducted an individual risk assessment. None of the contacts developed symptoms, and no addtional  at-risk individuals have been identified. 

Germany

    ° A  physician from the United States  working in the Democratic Republic of the Congo, was medically evacuated and treated in Germany in May 2026. The patient recovered and was discharged. No secondary cases were reported. 

    ° A second United States citizen, a humanitarian worker, tested positive for Bundibugyo virus in the Democratic Republic of Congo in July 2026 and was medically evacuated to a university hospital in Frankfurt/Main, Germany. The patient  is reported to be in stable condition.

Epidemiology

    ° Bundibugyo virus disease (BVD) is a severe Ebola disease caused by the Bundibugyo virus, one of the Orthoebolavirus species. It is a zoonotic disease, with fruit bats suspected to be the natural reservoir. 

    ° Human infection is thought to occur through close contact with the blood or secretions of infected wildlife, such as bats or non-human primates, and it subsequently spreads from person-to-person through direct contact with the blood, secretions, organs, or other bodily fluids of infected individuals or contaminated surfaces and materials. Transmission is particularly amplified in health-care settings when IPC measures are inadequate and during unsafe burial practices involving direct contact with deceased persons. 

    ° The incubation period for BVD ranges from 2 to 21 days, and infected individuals are not infectious until symptom onset. Early symptoms such as fever, fatigue, muscle pain, headache, and sore throat, are non-specific, which complicates clinical diagnosis and can delay detection. These symptoms then progress to gastrointestinal symptoms, organ dysfunction, and, in some cases, haemorrhagic manifestations. 

    ° CFRs in the past two BVD outbreaks, reported in Uganda and in the Democratic Republic of the Congo in 2007 and 2012 were 30% and 50%, respectively. 

    ° Differentiating BVD from other endemic febrile illnesses such as malaria is challenging without laboratory confirmation using PCR or antigen- or antibody-based assays. Outbreak control relies on rapid case identification, isolation and care, contact tracing, safe burials and strong community engagement, as no approved vaccines or specific treatments currently exist for BVD. 

Public health response

    ° Health authorities in the Democratic Republic of the Congo and Uganda, in collaboration with WHO and partners, continue to implement extensive public health measures, including implementing the continental response plan, engaging donors and mobilizing additional resources to address critical funding gaps and sustain response operations across affected and at-risk areas. 

    ° For further information about public health response actions by the respective Ministry of Health, WHO and partners, please refer to the latest situation reports published by the WHO Regional Office for Africa: Ebola Bundibugyo Virus Disease Outbreak Democratic Republic of the Congo | Uganda Weekly External Situation Report | WHO | Regional Office for Africa  

WHO risk assessment

    ° On 6 June 2026, WHO reassessed the risk of the outbreak of BVD to incorporate newly available information and align with the WHO Temporary Recommendations. The risk for countries sharing land borders with countries with documented Bundibugyo virus detection, the Democratic Republic of the Congo and Uganda at the time of assessment, has been separated from the risk for other countries in the African Region. 

    ° The risk in the Democratic Republic of the Congo remains assessed as very high due to ongoing transmission and the continued expansion of the outbreak into new health zones, increasing the potential for further national and regional spread. 

    ° The risk in Uganda is still assessed as high due to confirmed cross-border spread through imported cases and ongoing epidemiological links along the eastern Democratic Republic of the Congo–western Uganda corridor, which has historically been affected by Ebola outbreaks, including Bundibugyo virus and Sudan virus disease.  

    ° The risk for countries sharing land borders with countries reporting BDBV detection is assessed as high due to sustained population mobility linked to cross-border trade and mining activities, variation in capacities and experience of BVD response, and variable levels of readiness.  

    ° The risk for the rest of the African region and at the global level is assessed as low. 

    ° For further information, please see the WHO Rapid Risk Assessment – Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo, Uganda and countries with land borders adjoining countries with documented BDBV detection v3. 

(...)

Source: 

Link: https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON613

____